<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375332</url>
  </required_header>
  <id_info>
    <org_study_id>2019-05</org_study_id>
    <nct_id>NCT04375332</nct_id>
  </id_info>
  <brief_title>Beating Heart Mitral Valve Repair With the HARPOON™ System</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>A Prospective, Multi-center Trial to Evaluate the Safety and Effectiveness of Beating Heart Mitral Valve Repair With the HARPOON™ System (RESTORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System&#xD;
      in the treatment of patients with severe degenerative mitral regurgitation (DMR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESTORE is a prospective, multicenter, non-randomized trial designed to evaluate the safety&#xD;
      and effectiveness of the HARPOON™ Beating Heart Mitral Valve Repair System in patients with&#xD;
      severe degenerative mitral regurgitation (DMR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Safety Endpoints</measure>
    <time_frame>Discharge from the hospital or 30-days following the index procedure, whichever is longer.</time_frame>
    <description>Composite safety endpoint, defined as freedom-from all-cause mortality, stroke, acute kidney injury (AKI), major bleeding, new permanent pace-maker implantation, deep sternal wound infection (DSWI) or wound infection requiring surgical intervention, and prolonged mechanical ventilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Effectiveness Endpoints</measure>
    <time_frame>1 year following the index procedure.</time_frame>
    <description>Composite effectiveness endpoint, defined as freedom-from all-cause mortality, re-intervention on the mitral valve and recurrent [moderate or severe] MR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Product Usage</measure>
    <time_frame>Intraoperatively or post-operatively until discharge</time_frame>
    <description>Blood product usage intraoperatively or post-operatively until discharge, in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>First incision to incision close time</time_frame>
    <description>Procedure time: first incision to incision close time in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OR Time</measure>
    <time_frame>Entry to OR suite and exit from OR suite</time_frame>
    <description>OR time: entry to OR suite and exit from OR suite in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ventilation Hours</measure>
    <time_frame>Discharge</time_frame>
    <description>Total ventilation hours at discharge in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hours in ICU</measure>
    <time_frame>Post index procedure until discharge</time_frame>
    <description>Total hours in the ICU post index procedure until discharge in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving mitral valve replacement (MVR)</measure>
    <time_frame>During Index Procedure</time_frame>
    <description>Percentage of subjects receiving mitral valve replacement (MVR) during the index procedure in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay (LOS)</measure>
    <time_frame>Post index procedure until discharge</time_frame>
    <description>Hospital length of stay (LOS) post index procedure until discharge in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Effectiveness Endpoint</measure>
    <time_frame>One year following the index procedure</time_frame>
    <description>Composite effectiveness endpoint, defined as freedom from all-cause mortality, re-intervention on the mitral valve and recurrent (moderate or severe) mitral regurgitation (MR) for one year following the index procedure, in the HARPOON System treatment arm vs. CTSN-TR comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharged to Home vs. Other Facility</measure>
    <time_frame>Discharge</time_frame>
    <description>Discharged to home vs. other facility, in the HARPOON System treatment arm vs. open surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>HARPOON™ Beating Heart Mitral Valve Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HARPOON™ Beating Heart Mitral Valve Repair System</intervention_name>
    <description>Repair of the chordae tendinae in the mitral valve.</description>
    <arm_group_label>HARPOON™ Beating Heart Mitral Valve Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject is required to meet all of the following inclusion criteria:&#xD;
&#xD;
          1. Patient is &gt;/= 21 years old.&#xD;
&#xD;
          2. Presence of severe degenerative mitral regurgitation with isolated mid-segment&#xD;
             posterior leaflet prolapse by echocardiographic study.&#xD;
&#xD;
          3. Mitral leaflet coaptation surface sufficient to reduce mitral regurgitation without&#xD;
             undue leaflet tension, based on the judgment of the Echocardiographic Core Lab.&#xD;
&#xD;
          4. Patient competent to sign informed consent and able to return for follow-up and is&#xD;
             capable of participating in all testing associated with this clinical investigation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if ANY of the following criteria apply:&#xD;
&#xD;
          1. Functional mitral regurgitation (FMR).&#xD;
&#xD;
          2. Evidence of anterior or bileaflet prolapse.&#xD;
&#xD;
          3. Severe mitral annular calcification (MAC).&#xD;
&#xD;
          4. Moderate or greater leaflet calcification.&#xD;
&#xD;
          5. Fragile or thinning apex (e.g. LV aneurysm).&#xD;
&#xD;
          6. Have undergone cardiac or peripheral vascular procedures within 30 days prior to the&#xD;
             trial procedure.&#xD;
&#xD;
          7. Planned cardiac or peripheral vascular procedures within 30 days after the trial&#xD;
             procedure.&#xD;
&#xD;
          8. Requirement for concomitant cardiac surgery.&#xD;
&#xD;
          9. Severe pulmonary hypertension (pulmonary artery systolic pressure &gt; 60mmHg).&#xD;
&#xD;
         10. Severe aortic stenosis or insufficiency.&#xD;
&#xD;
         11. Severe tricuspid regurgitation. (Patients with mild or moderate tricuspid&#xD;
             regurgitation are not excluded.)&#xD;
&#xD;
         12. Left ventricular ejection fraction (LVEF) &lt;30%, or severely impaired right ventricular&#xD;
             dysfunction as measured by the core lab.&#xD;
&#xD;
         13. Any history of endocarditis.&#xD;
&#xD;
         14. Contraindication to cardiac surgery, including hostile chest or history of mediastinal&#xD;
             radiation.&#xD;
&#xD;
         15. Previous structural heart intervention (e.g. any heart valve replacement or repair&#xD;
             procedures). Previous percutaneous coronary intervention (PCI) is allowed.&#xD;
&#xD;
         16. Previous coronary artery bypass grafting (CABG).&#xD;
&#xD;
         17. Stroke within 30 days prior to index procedure.&#xD;
&#xD;
         18. ST segment elevation myocardial infarction (STEMI) requiring intervention within 30&#xD;
             days prior to index procedure.&#xD;
&#xD;
         19. Evidence of cirrhosis or hepatic synthetic failure (Child-Pugh Class B or higher, [or&#xD;
             MELD score of ≥ 13]).&#xD;
&#xD;
         20. Renal insufficiency CKD Stage 3b or worse (GFR &lt; 45 ml/min/1.73 m2).&#xD;
&#xD;
         21. Hemodynamic instability or cardiogenic shock at the time of enrollment (e.g. requiring&#xD;
             inotropic support or mechanical support devices).&#xD;
&#xD;
         22. History of bleeding diathesis or coagulopathy or leukopenia (WBC &lt; 3000 mcL) or acute&#xD;
             anemia (Hb &lt; 9 g/dL) or thrombocytopenia (platelets &lt; 50,000 cells mcL).&#xD;
&#xD;
         23. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with&#xD;
             COVID-19 with sequelae that could confound endpoint assessments (as assessed by Case&#xD;
             Review Committee).&#xD;
&#xD;
         24. Refuse blood products.&#xD;
&#xD;
         25. Planned treatment with any other investigational device or procedure through 1-year&#xD;
             follow-up, or who are currently participating in an investigational drug or device&#xD;
             trial.&#xD;
&#xD;
         26. Carotid stenosis ≥ to 80% at time of enrollment.&#xD;
&#xD;
         27. Rheumatic heart disease including rheumatic mitral stenosis.&#xD;
&#xD;
         28. Pregnant or lactating at the time of enrollment (women of childbearing age should have&#xD;
             negative pregnancy test within 72 hours of surgery) or planning pregnancy within the&#xD;
             next 12 months.&#xD;
&#xD;
         29. Concurrent medical condition with a life expectancy of less than 12 months in the&#xD;
             judgment of the Investigator.&#xD;
&#xD;
         30. Condition or conditions that, in the opinion of the Investigator, precludes&#xD;
             participation, including willingness to comply with all follow-up procedures.&#xD;
&#xD;
         31. Contraindication for transesophageal echocardiography (TEE), including esophageal&#xD;
             spasm, esophageal stricture, esophageal laceration, esophageal perforation, esophageal&#xD;
             diverticula (e.g. Zenker's diverticulum).&#xD;
&#xD;
         32. Echocardiographic evidence of intracardiac mass (e.g. left ventricular, atrial, or&#xD;
             appendage thrombus, myxoma, or vegetation).&#xD;
&#xD;
         33. Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen.&#xD;
&#xD;
             Intra-operative exclusion criteria&#xD;
&#xD;
         34. No longer meets eligibility criteria based on intra-operative assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinod H. Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Cardiovascular Surgery, Piedmont Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstantinos Koulogiannis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Medicine Gagnon Cardiovascular Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Reynolds</last_name>
    <phone>949-250-6849</phone>
    <email>jason_reynolds@edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mullin</last_name>
      <phone>323-442-6226</phone>
      <email>Stephanie.Mullin@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Cunningham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Satou, RN</last_name>
      <phone>310-206-4168</phone>
      <email>nsatou@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Shemin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Flores</last_name>
      <phone>650-725-8718</phone>
      <email>Tflores2@Stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John MacArthur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Matheus</last_name>
      <phone>628-206-4624</phone>
      <email>Marcela.Matheus@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vaikom Mahadevan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Cloutier</last_name>
      <phone>860-972-2579</phone>
      <email>Jill.Cloutier@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Sabet Hashim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Houser</last_name>
      <phone>407-303-9418</phone>
      <email>sandra.houser@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Accola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Health Care System</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Lindner</last_name>
      <phone>941-917-1669</phone>
      <email>colleen-lindner@smh.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Hoffberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise White</last_name>
      <phone>404-605-3561</phone>
      <email>Denise.whyte@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Federico Milla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheree Slusher</last_name>
      <phone>317-583-7804</phone>
      <email>Cheree.Slusher@ascension.org</email>
    </contact>
    <investigator>
      <last_name>David Heimansohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Fleischmann</last_name>
      <phone>410-328-8093</phone>
      <email>EFleischmann@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Murtaza Dawood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Winship</last_name>
      <phone>617-724-7629</phone>
      <email>TWINSHIP@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Serguei Melnitchouk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>China Green</last_name>
      <phone>734-936-7731</phone>
      <email>chjgreen@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Romano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sundt</last_name>
      <phone>507-293-4234</phone>
      <email>Sundt.Wendy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Arman Arghami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish/Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Koogler</last_name>
      <phone>314-362-3043</phone>
      <email>Kooglerk@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Spencer Melby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Bukhari</last_name>
      <phone>973-971-8597</phone>
      <email>Jessica.Bukhari@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>John Brown III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Palaparthi</last_name>
      <phone>212-746-5594</phone>
      <email>ntp2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Mick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Casalinova</last_name>
      <phone>919-613-5621</phone>
      <email>sarah.casalinova@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Gaca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Laverty</last_name>
      <email>Eva.Laverty-Wilson@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Wilson Szeto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Galuska</last_name>
      <phone>412-359-3802</phone>
      <email>veronica.galuska2@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Walter McGregor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC/Pinnacle Health Hospitals</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Hollister, RN</last_name>
      <email>hollisterr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry McDermott</last_name>
      <phone>484-476-8579</phone>
      <email>McDermottS@MLHS.ORG</email>
    </contact>
    <investigator>
      <last_name>Basel Ramlawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Merkelz</last_name>
      <phone>615-981-1689</phone>
      <email>Brenda.Merkelz@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Sreekumar Subramanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Heart Institute</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hummel</last_name>
      <phone>801-507-4731</phone>
      <email>Erika.Hummel@imail.org</email>
    </contact>
    <investigator>
      <last_name>John Doty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

